Catyalyst Pharmaceutical (CPRX) Posts Narrower than Expected Q2 Loss of 1c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Dow, S&P 500 fall, tech steadies to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude jumps to highest since April on Houthi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts CPRX Hot Sheet
Price: $31.49 --0%
Financial Fact:
Research and development: 2.49M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Financial Fact:
Research and development: 2.49M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Catyalyst Pharmaceutical Partners (NASDAQ: CPRX) reported Q2 EPS of ($0.01), $0.04 better than the analyst estimate of ($0.05).
For earnings history and earnings-related data on Catyalyst Pharmaceutical Partners (CPRX) click here.
For earnings history and earnings-related data on Catyalyst Pharmaceutical Partners (CPRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Lockheed Martin (LMT) PT Raised to $692 at UBS
- Booz Allen Hamilton falls despite earnings beat
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
